Brief: CNS Pharmaceuticals Announces Preliminary Results From Ongoing Trial Evaluating Berubicin For Treatment Of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals

08/12/2022 17:15

Dec 8 (Reuters) - CNS Pharmaceuticals Inc  CNSP.O :
    * CNS PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS FROM
ONGOING
POTENTIALLY PIVOTAL TRIAL EVALUATING BERUBICIN FOR THE TREATMENT
OF RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    * CNS PHARMACEUTICALS -CONTINUED PROGRESS TOWARD PLANNED
INTERIM
ANALYSIS WHEN 30-50% OF SUBJECTS EVALUABLE AT 6 MONTHS AFTER
ENROLLMENT, EXPECTED MID-YEAR 2023
    * CNS PHARMACEUTICALS - BERUBICIN CONTINUES TO DEMONSTRATE
ABILITY
TO BE INNOVATIVE TREATMENT IN GBM AS SAFE AND POTENTIALLY
EFFECTIVE THERAPY
    * CNS PHARMACEUTICALS - ALL GRADES OF ADVERSE EVENTS
OCCURRING IN
MORE THAN 5% OF PATIENTS, GRADE 3-5 EVENTS, ALSO SIMILAR IN
BERUBICIN, LOMUSTINE ARMS

Source text for Eikon:  ID:nPn4fTZ2ta 
Further company coverage:  CNSP.O 
 ((Reuters.Briefs@thomsonreuters.com;))